Orlistat e rischio cardiovascolare

Translated title of the contribution: Orlistat and cardiovascular risk

Giuseppe Derosa, Mario N. Piccinni

Research output: Contribution to journalArticlepeer-review


Long term weight reduction has been associated with favourable effects on many cardiovascular risk factors. Orlistat administration in obese patients has been associated with improvement of glucose tolerance and reduction in the incidence of type 2 diabetes. Furthermore, well conducted trials demonstrated the ability of orlistat to reduce many cardiovascular risk factors: hypertension, total and low density lipoprotein (LDL) cholesterol levels and low density lipoprotein cholesterol/high density lipoprotein cholesterol ratio (LDL/HDL ratio). More recently orlistat has yet been involved in the modulation of some inflammatory markers. Data available from intervention trials suggest that weight loss reduces coronary heart disease risk factors in obese persons and the risk factor reduction is significantly enhanced with administration of orlistat.

Translated title of the contributionOrlistat and cardiovascular risk
Original languageItalian
Pages (from-to)169-178
Number of pages10
JournalTrends in Medicine
Issue number2
Publication statusPublished - Apr 2006

ASJC Scopus subject areas

  • Internal Medicine
  • Pharmacology (medical)


Dive into the research topics of 'Orlistat and cardiovascular risk'. Together they form a unique fingerprint.

Cite this